IPIG Friday Satellite Symposium
Friday, December 11, 2026 | 7:00–10:00 AM · New Orleans, LA · Held in conjunction with the ASH Annual Meeting

About this program

PNH care has advanced faster than the evidence base supporting it. Complement inhibition has expanded well beyond terminal blockade, yet clinicians still face fundamental questions with no settled answer: when does a clone become a disease, how long anticoagulation should continue, and how breakthrough hemolysis should be distinguished from extravascular hemolysis in a patient who is improving but not well.

This symposium translates the findings of IPIG’s international Delphi initiative into a high-impact, case-driven educational program. Rather than presenting a single authoritative voice, the symposium deploys expert faculty to present competing positions on the most consequential unresolved questions in PNH — grounded in seven real-world clinical cases spanning disease definition, thrombosis management, and hemolysis classification.

Where the Delphi panel reached consensus, faculty will say so and explain what drove it. Where it did not, attendees will see the disagreement argued in the open by the clinicians who hold those positions — and will understand exactly which patient will be affected by the outcome.

Format

Seven clinical cases, each introduced with the actual decision point that confronted the treating team. Two faculty members then argue opposing management approaches before the Delphi result is revealed and the floor is opened to the audience. The session closes with a working discussion of how these findings will shape forthcoming IPIG guidance.

Who should attend

Hematologists, PNH-treating clinicians, advanced practice providers, fellows, nurses, pharmacists, and researchers involved in the diagnosis and long-term management of paroxysmal nocturnal hemoglobinuria.

Learning objectives

Upon completion, participants will be able to:

• Apply current diagnostic thresholds for PNH clone size to real-world clinical scenarios, and articulate where expert consensus remains unsettled
• Evaluate competing strategies for thrombosis prophylaxis and anticoagulation duration in patients on complement inhibition
• Differentiate breakthrough hemolysis from extravascular hemolysis and select appropriate management for each
• Describe how the IPIG Delphi methodology translates areas of expert disagreement into actionable clinical guidance

For more information and to register click here IPIG Friday Satellite Symposia at ASH 2026